This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Cullinan Therapeutics Immunology Day Data
Business clinical data presentation

Cullinan Therapeutics Immunology Day Data

Analysis based on 7 articles · First reported May 26, 2026 · Last updated May 26, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The presentation of new clinical data for CLN-978 and velinotamig by Cullinan Therapeutics could lead to increased investor confidence and a positive impact on the company's stock price. Positive data could also signal advancements in the treatment of autoimmune diseases, potentially benefiting the broader biotechnology and pharmaceutical sectors.

Biotechnology Pharmaceuticals
Event Summary

Cullinan Therapeutics, a clinical-stage biopharmaceutical company, announced it will host an in-person Immunology Day event in New York City on June 10, 2026. The event will feature new and updated clinical data from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies for its product candidates, CLN-978 and velinotamig. Initial data from the first multi-dose cohorts of both the RA study for CLN-978 and the velinotamig study will be presented. Nadim Ahmed, President and CEO of Cullinan Therapeutics, will provide deeper insight into the data and the company's global development strategy. Key opinion leaders Dr. Ricardo Grieshaber-Bouyer and Dr. John Tesser will also share their clinical perspectives. The company aims to validate the potential of T cell engagers in autoimmune diseases and drive value for patients and shareholders.

Entities Involved
stock
Cullinan Therapeutics
Cullinan Therapeutics is hosting an Immunology Day to present new clinical data for its autoimmune disease therapies, CLN-978 and velinotamig, which could significantly impact its stock price and future development.
Importance 100.0 Sentiment 60.0
oth
CLN-978
CLN-978 is a CD19xCD3 T cell engager being developed by Cullinan Therapeutics for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). New clinical data will be presented, potentially validating its efficacy.
Importance 80.0 Sentiment 60.0
oth
Velinotamig
Velinotamig is a BCMAxCD3 T cell engager being developed by Cullinan Therapeutics for treatment-refractory autoimmune diseases. Initial multi-dose cohort data will be shared, which could influence its development path.
Importance 80.0 Sentiment 60.0
per
Nadim Ahmed
Nadim Ahmed, President and CEO of Cullinan Therapeutics, will provide deeper insight into the clinical data and the company's strategy, influencing investor perception.
Importance 70.0 Sentiment 60.0
per
Ricardo Grieshaber-Bouyer
Dr. Ricardo Grieshaber-Bouyer, a key opinion leader, will share clinical perspectives on the data presented by Cullinan Therapeutics, adding credibility to the findings.
Importance 40.0 Sentiment 50.0
per
John Tesser
Dr. John Tesser, a key opinion leader, will share clinical perspectives on the data presented by Cullinan Therapeutics, contributing to the discussion and analysis of the therapies.
Importance 40.0 Sentiment 50.0
priv
Genrix Bio
Genrix Bio is involved in a study in China for velinotamig, and initial data from this study will be shared, indicating international development efforts.
Importance 30.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.